Humacyte (HUMA) News Today $1.69 +0.05 (+2.74%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$1.68 -0.01 (-0.89%) As of 08:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HUMA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Weiss Ratings Reiterates Sell (E+) Rating for Humacyte (NASDAQ:HUMA)4 hours ago | marketbeat.comHumacyte Gains 43%, Insider Trades Reap BenefitOctober 7 at 7:33 PM | finance.yahoo.comHumacyte: Shares Tank On Fundraising News - What You Need To KnowOctober 7 at 7:33 PM | seekingalpha.comInvestors Buy High Volume of Call Options on Humacyte (NASDAQ:HUMA)October 7 at 5:25 PM | marketbeat.comHumacyte shares plunge after announcing $60 million registered direct offeringOctober 7 at 2:31 PM | msn.comHumacyte shares sink as it announces pricing of $60M direct offeringOctober 7 at 2:31 PM | msn.comHumacyte Shares Tumble After Stock Offering Gets PricedOctober 7 at 2:31 PM | marketwatch.comHumacyte stock tumbles after $60 million registered direct offeringOctober 7 at 9:30 AM | investing.comHumacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct OfferingOctober 7 at 9:00 AM | globenewswire.comHumacyte announces publication of Symvess results in real-world combatOctober 6 at 5:05 PM | msn.comHumacyte rises after positive data from humanitarian study of SymvessOctober 6 at 5:05 PM | msn.comHumacyte's (HUMA) "Buy" Rating Reiterated at D. Boral CapitalOctober 6 at 2:12 PM | marketbeat.comHumacyte, Inc. Reports Zero Infections and High Patency Rates for Symvess in Military Medicine Journal Publication on Wartime Vascular Trauma TreatmentOctober 6 at 8:31 AM | quiverquant.comQHumacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™October 6 at 8:00 AM | globenewswire.comD. Boral Capital Maintains Humacyte (HUMA) Buy RecommendationSeptember 30, 2025 | msn.comHumacyte (HUMA) Price Target Increased by 51.64% to 9.44September 30, 2025 | msn.comD. Boral Capital Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA)September 30, 2025 | marketbeat.comHumacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered EsophagusSeptember 29, 2025 | globenewswire.comHumacyte, Inc. (NASDAQ:HUMA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSeptember 20, 2025 | marketbeat.comHumacyte announces preclinical data on CTEV useSeptember 19, 2025 | msn.comHumacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)September 18, 2025 | globenewswire.comHumacyte Amends Revenue Agreement with TPC InvestmentsSeptember 18, 2025 | tipranks.comHumacyte announces publication of outcomes for patients treated with SymvessSeptember 15, 2025 | msn.comHumacyte, Inc. Announces Positive Outcomes for Symvess in Journal of Vascular Surgery PublicationSeptember 15, 2025 | quiverquant.comQHumacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™September 15, 2025 | globenewswire.comHumacyte, Inc. $HUMA Shares Purchased by Woodline Partners LPSeptember 15, 2025 | marketbeat.comHumacyte files $350M mixed securities shelfSeptember 13, 2025 | msn.comPolar Asset Management Partners Inc. Takes Position in Humacyte, Inc. $HUMASeptember 9, 2025 | marketbeat.com294,392 Shares in Humacyte, Inc. $HUMA Acquired by Nuveen LLCSeptember 7, 2025 | marketbeat.comRA Capital Management L.P. Invests $5.65 Million in Humacyte, Inc. $HUMASeptember 4, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) Upgraded by Barclays to "Strong-Buy" RatingAugust 31, 2025 | marketbeat.comHumacyte, Inc. Stock (HUMA) Opinions on Barclays Coverage InitiationAugust 30, 2025 | quiverquant.comQHeights Capital Management Inc. Takes Position in Humacyte, Inc. $HUMAAugust 30, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Receives Consensus Rating of "Buy" from AnalystsAugust 28, 2025 | marketbeat.comHumacyte initiated with an Overweight at BarclaysAugust 27, 2025 | msn.comMonashee Investment Management LLC Buys New Shares in Humacyte, Inc. $HUMAAugust 23, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) CEO Laura Niklason Sells 591,685 SharesAugust 21, 2025 | insidertrades.com1,049,828 Shares in Humacyte, Inc. $HUMA Acquired by Maven Securities LTDAugust 21, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) Downgraded by Wall Street Zen to "Sell"August 18, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for Humacyte Q3 Earnings?August 16, 2025 | marketbeat.comFY2029 EPS Estimates for Humacyte Cut by HC WainwrightAugust 15, 2025 | marketbeat.comTD Cowen Cuts Humacyte (NASDAQ:HUMA) Price Target to $3.50August 13, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) Price Target Cut to $3.00 by Analysts at HC WainwrightAugust 13, 2025 | marketbeat.comHumacyte’s Earnings Call: Progress Amid ChallengesAugust 13, 2025 | msn.comHumacyte Inc. (HUMA) Stock Price Today - WSJAugust 12, 2025 | wsj.comDurham biotech sees stock plunge on slow salesAugust 12, 2025 | bizjournals.comHumacyte, Inc. (NASDAQ:HUMA) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comHumacyte: Cash Burn And A Glacial Launch Overshadow VAC ProgressAugust 12, 2025 | seekingalpha.comD. Boral Capital Reaffirms "Buy" Rating for Humacyte (NASDAQ:HUMA)August 12, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) Posts Earnings Results, Misses Estimates By $0.09 EPSAugust 12, 2025 | marketbeat.com Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HUMA Media Mentions By Week HUMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HUMA News Sentiment▼0.340.63▲Average Medical News Sentiment HUMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HUMA Articles This Week▼157▲HUMA Articles Average Week Get the Latest News and Ratings for HUMA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Humacyte and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SDGR News Today HROW News Today PAHC News Today RCUS News Today HRMY News Today AUPH News Today STOK News Today EVO News Today AVDL News Today ORIC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HUMA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
